A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Agitation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Imaging Endpoints · Scottsdale, AZ
Florida · 4
- Nuovida Research Center · Miami, FL
- Progressive Medical Research · Port Orange, FL
- IPTB Clinical Research · Tampa, FL
- Hope Research Network - Miami · Virginia Gardens, FL
Massachusetts · 1
- Boston Center for Memory · Newton, MA
Nevada · 1
- Redbird Research · Las Vegas, NV
North Carolina · 1
- West Clinical Research · Morehead City, NC
Texas · 1
- Epic Medical Research, LLC - Carrolton · Carrollton, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.